



SEQUENCE LISTING

<110> SAIKAWA, Akira
IGARI, Yasutaka
HATA, Yoshio
YAMAMOTO, Kazumichi

<120> Sustained-Release Composition, Method of its Preparation and Use Thereof

<130> 2500US1P
<140> 10/799,320
<141> 2004-03-12

<150> 09/582,926
<151> 2000-07-05

<150> PCT/JP99/00086
<151> 1999-01-13

<150> JP 10-6412
<151> 1998-01-16

<160> 5

<170> PatentIn version 3.0

<210> 1
<211> 10
<212> PRT
<213> artificial sequence

<220>
<223> LH-RH derived peptide

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro carboxy terminal

<220>
<221> MOD_RES
<222> (6)..(6)
<223> DLeu, DAla, DTrp, DSer(tbut), D2Nal or Dhis(ImBzl)

<220>
<221> MOD_RES
<222> (10)..(10)
<223> NH-C2H5 or Gly-NH2

<400> 1

Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa
1 5 10

<210> 2
 <211> 11
 <212> PRT
 <213> artificial sequence

 <220>
 <223> LH-RH antagonist derivatives

 <220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> N(4H2-furoyl)Gly or NAc

 <220>
 <221> MOD_RES
 <222> (2)..(2)
 <223> X is D2Nal

 <220>
 <221> MOD_RES
 <222> (3)..(3)
 <223> X is D4ClPhe

 <220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> X is D3Pal

 <220>
 <221> MOD_RES
 <222> (6)..(6)
 <223> NMeTyr, Tyr, Aph(Atz) or NMeAph(Atz)

 <220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> DLys(Nic), DCit, DLys(AzaGlyNic),

 <220>
 <221> MOD_RES
 <222> (7)..(7)
 <223> DLys(AzaGlyFur), DhArg(Et2), DAph(Atz), or DhC

 <220>
 <221> MOD_RES
 <222> (9)..(9)
 <223> Lys(Nisp), Arg or HArg(Et2)

 <220>

<221> MOD_RES
<222> (11)..(11)
<223> X is DAlaNH2

<400> 2

Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1 5 10

<210> 3
<211> 8
<212> PRT
<213> artificial sequence

<220>
<223> LH-RH derived peptides

<220>
<221> MOD_RES
<222> (1)..(1)
<223> 5-oxo-Pro carboxy terminal

<220>
<221> MOD_RES
<222> (6)..(6)
<223> X is DLeu

<220>
<221> MOD_RES
<222> (8)..(8)
<223> Pro-NH-C2H5 amino terminal

<400> 3

Pro His Trp Ser Tyr Xaa Arg Pro
1 5

<210> 4
<211> 11
<212> PRT
<213> artificial sequence

<220>
<223> LH-RH derived peptides

<220>
<221> MOD_RES
<222> (1)..(1)
<223> N-(S)-tetrahydrofur-2-oyl-Gly

<220>

<221> MOD_RES
<222> (2)..(2)
<223> X is D2Nal

<220>
<221> MOD_RES
<222> (3)..(3)
<223> X is D4ClPhe

<220>
<221> MOD_RES
<222> (4)..(4)
<223> X is D3Pal

<220>
<221> MOD_RES
<222> (6)..(6)
<223> X is NMeTyr

<220>
<221> MOD_RES
<222> (7)..(7)
<223> X is DLys(Nic)

<220>
<221> MOD_RES
<222> (9)..(9)
<223> X is Lys(Nisp)

<220>
<221> MOD_RES
<222> (11)..(11)
<223> X is DAlaNH2

<400> 4

Gly Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1 5 10

<210> 5
<211> 9
<212> PRT
<213> artificial sequence

<220>
<223> LH-RH derived peptides

<220>
<221> MOD_RES
<222> (1)..(1)

<223> 5-oxo-Pro carboxy terminal

<220>

<221> MOD_RES

<222> (6)..(6)

<223> X is DLeu

<220>

<221> MOD_RES

<222> (9)..(9)

<223> Pro-NH-C2H5 amino terminal

<400> 5

Pro His Trp Ser Tyr Xaa Leu Arg Pro
1 5